MX2018006026A - Un ligante de receptor de adenosina a3 para uso en el tratamiento de la acumulacion de grasa ectopica. - Google Patents
Un ligante de receptor de adenosina a3 para uso en el tratamiento de la acumulacion de grasa ectopica.Info
- Publication number
- MX2018006026A MX2018006026A MX2018006026A MX2018006026A MX2018006026A MX 2018006026 A MX2018006026 A MX 2018006026A MX 2018006026 A MX2018006026 A MX 2018006026A MX 2018006026 A MX2018006026 A MX 2018006026A MX 2018006026 A MX2018006026 A MX 2018006026A
- Authority
- MX
- Mexico
- Prior art keywords
- fat accumulation
- ligand
- treating
- ectopic fat
- present disclosure
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente descripción se relaciona con ligando de A?AR para reducir acumulación de grasa ectópica, particularmente en hígado graso. También se proporciona por la presente descripción el uso de ligando de A?AR para la preparación de una composición farmacéutica para reducir la acumulación de grasa, método para tratar una condición que se asocia con acumulación de grasa que hace uso del ligando y kit que comprende composiciones farmacéuticas que comprenden el ligando, e instrucciones para uso de las mismas, para tratar una condición asociada con acumulación de grasa ectópica. En una modalidad, la presente descripción proporciona el uso de un agonista de A?AR, como por ejemplo 2-cloro-N6-(3-yodobencil)-adenosin-5'-N-metiluronamida (CI-IB-MECA, CF102) para tratar hígado graso, específicamente, enfermedad de hígado graso no alcohólico (NAFLD).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL242723A IL242723B (en) | 2015-11-23 | 2015-11-23 | A3 adenosine receptor ligand for the treatment of ectopic fat accumulation |
| PCT/IL2016/051258 WO2017090036A1 (en) | 2015-11-23 | 2016-11-22 | An a3 adenosine receptor ligand for use in treating ectopic fat accumulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018006026A true MX2018006026A (es) | 2019-01-28 |
Family
ID=57485841
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018006026A MX2018006026A (es) | 2015-11-23 | 2016-11-22 | Un ligante de receptor de adenosina a3 para uso en el tratamiento de la acumulacion de grasa ectopica. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10780106B2 (es) |
| EP (1) | EP3380104B1 (es) |
| JP (2) | JP6980655B2 (es) |
| KR (1) | KR102103657B1 (es) |
| CN (1) | CN108367016B (es) |
| BR (1) | BR112018010391A8 (es) |
| CA (1) | CA3005961C (es) |
| DK (1) | DK3380104T3 (es) |
| ES (1) | ES2848150T3 (es) |
| HR (1) | HRP20210020T1 (es) |
| HU (1) | HUE053558T2 (es) |
| IL (3) | IL242723B (es) |
| LT (1) | LT3380104T (es) |
| MX (1) | MX2018006026A (es) |
| PL (1) | PL3380104T3 (es) |
| PT (1) | PT3380104T (es) |
| RS (1) | RS61372B1 (es) |
| SI (1) | SI3380104T1 (es) |
| WO (1) | WO2017090036A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL254535A0 (en) * | 2017-09-17 | 2017-11-30 | Can Fite Biopharma Ltd | Adenosine a3 receptor ligand for use in the management of cytokine release syndrome |
| IL264112A (en) * | 2019-01-06 | 2020-07-30 | Fishman Pnina | Adenosine a3 receptor ligand for use in lowering adipocyte levels |
| IL272078A (en) | 2020-01-16 | 2021-07-29 | Can Fite Biopharma Ltd | Cannabinoids for use in therapy |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5443836A (en) | 1993-03-15 | 1995-08-22 | Gensia, Inc. | Methods for protecting tissues and organs from ischemic damage |
| US5688774A (en) | 1993-07-13 | 1997-11-18 | The United States Of America As Represented By The Department Of Health And Human Services | A3 adenosine receptor agonists |
| EP0708781B1 (en) | 1993-07-13 | 2001-10-04 | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services | A 3 adenosine receptor agonists |
| WO1997027173A2 (en) | 1996-01-24 | 1997-07-31 | Sumitomo Chemical Company, Limited | Dihalopropene compounds, their use as insecticides/acaricides and intermediates for their production |
| US6048865A (en) | 1997-07-29 | 2000-04-11 | Medco Research, Inc. | N6 -substituted-adenosine-5'-uronamides as adenosine receptor modulator |
| EP1019427A4 (en) | 1997-07-29 | 2000-07-19 | Medco Res Inc | N? 6 -SUBSTITUES-ADENOSINE-5'-URONAMIDES USEFUL AS MODULATORS OF ADENOSINE RECEPTORS |
| WO1999020284A1 (en) | 1997-10-23 | 1999-04-29 | Trustees Of The University Of Pennsylvania | Methods for reducing ischemic injury of the heart via the sequential administration of monophosphoryl lipid a and adenosine receptor agents |
| IL133680A0 (en) | 1999-09-10 | 2001-04-30 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
| CA2434906C (en) * | 2001-01-16 | 2008-08-19 | Can-Fite Biopharma Ltd. | Use of an adenosine a3 receptor agonist for inhibition of viral replication |
| EP1983990B1 (en) | 2006-01-26 | 2011-03-23 | Government of the United States of America, Represented by the Secretary, Department of Health and Human Services | A3 adenosine receptor allosteric modulators |
| DK2227234T3 (da) * | 2007-10-15 | 2014-08-11 | Can Fite Biopharma Ltd | Fremgangsmåde til induktion af hepatocytproliferering og anvendelserderaf |
| US20150018299A1 (en) | 2012-01-23 | 2015-01-15 | Can-Fite Biopharma Ltd. | Treatment of liver conditions |
-
2015
- 2015-11-23 IL IL242723A patent/IL242723B/en active IP Right Grant
-
2016
- 2016-11-22 CA CA3005961A patent/CA3005961C/en active Active
- 2016-11-22 PL PL16806299T patent/PL3380104T3/pl unknown
- 2016-11-22 JP JP2018526535A patent/JP6980655B2/ja active Active
- 2016-11-22 HU HUE16806299A patent/HUE053558T2/hu unknown
- 2016-11-22 LT LTEP16806299.0T patent/LT3380104T/lt unknown
- 2016-11-22 PT PT168062990T patent/PT3380104T/pt unknown
- 2016-11-22 SI SI201631045T patent/SI3380104T1/sl unknown
- 2016-11-22 KR KR1020187016840A patent/KR102103657B1/ko active IP Right Grant
- 2016-11-22 DK DK16806299.0T patent/DK3380104T3/da active
- 2016-11-22 BR BR112018010391A patent/BR112018010391A8/pt not_active Application Discontinuation
- 2016-11-22 RS RS20210079A patent/RS61372B1/sr unknown
- 2016-11-22 ES ES16806299T patent/ES2848150T3/es active Active
- 2016-11-22 EP EP16806299.0A patent/EP3380104B1/en active Active
- 2016-11-22 CN CN201680068558.0A patent/CN108367016B/zh active Active
- 2016-11-22 IL IL289841A patent/IL289841B/en unknown
- 2016-11-22 MX MX2018006026A patent/MX2018006026A/es unknown
- 2016-11-22 WO PCT/IL2016/051258 patent/WO2017090036A1/en active Application Filing
-
2018
- 2018-05-16 IL IL259396A patent/IL259396B/en unknown
- 2018-05-22 US US15/986,332 patent/US10780106B2/en active Active
-
2020
- 2020-02-10 JP JP2020020917A patent/JP6990934B2/ja active Active
- 2020-08-26 US US17/003,191 patent/US11291681B2/en active Active
-
2021
- 2021-01-07 HR HRP20210020TT patent/HRP20210020T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2022002771A1 (es) | Anticuerpos madurados por afinidad y humanizados para fcrh5 y su uso (divisional de cl 201703195). | |
| CU20190057A7 (es) | Composiciones que comprenden aminoácidos | |
| AR100215A1 (es) | Conjugados de anticuerpo-fármaco anti-ptk7 | |
| MX2015011690A (es) | Composiciones de azucares mezclados. | |
| WO2016001754A3 (en) | Methods for three dimensional reconstruction and determining the quality of an embryo | |
| SG10201902831UA (en) | Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers | |
| MX2016014147A (es) | Composiciones de proteina soluble y metodos para su elaboracion. | |
| SG10201806854XA (en) | Compositions comprising 15-ohepa and methods of using the same | |
| MX2018006026A (es) | Un ligante de receptor de adenosina a3 para uso en el tratamiento de la acumulacion de grasa ectopica. | |
| WO2019039817A3 (ko) | 간질환 예측 또는 진단용 조성물 및 이를 이용한 간질환 예측 또는 진단 방법 | |
| EP3285071A4 (en) | Biomarker composition for diagnosing still's disease, diagnostic kit, and diagnostic method | |
| MX2020008125A (es) | Composiciones que comprenden berberina. | |
| ZA201705173B (en) | In vitro method for estimating in vivo protein digestibility | |
| SG11202103646UA (en) | Health-care product composition for enriching asthenic disease, preparation method therefor and use thereof | |
| PH12019502694A1 (en) | Anti-trkb antibodies | |
| AR097143A1 (es) | Composición alimenticia mineral para lamer para rumiantes y método para prepararla | |
| EP3677126A4 (en) | COMPOSITION OF AGE INHIBITORS, ITS USE, PROCESS OF PREPARATION AND ITS FORMULATION | |
| MX2017009929A (es) | Composiciones y métodos para metabolismo muscular mejorado. | |
| AR098035A1 (es) | Composición alimenticia para animales rumiantes que contiene proteínas y método de preparación | |
| EA201892722A2 (ru) | Мелассовый порошок и способ его получения | |
| MX2019008535A (es) | Agonista del ppar gamma para el tratamiento de la enfermedad de huntington. | |
| MX2016002714A (es) | Composicion y metodo para tropicalizar chocolate. | |
| NZ742210A (en) | Neospora vaccine composition | |
| PH12016501390A1 (en) | Nutritional compositions containing ceramide | |
| TW201613489A (en) | Hydrolyzed lactose-containing nutritional compositions and uses thereof |